PrecisionLife announces strategic CNS drug development collaboration with Nanopharmaceutics
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Subscribe To Our Newsletter & Stay Updated